DEXUS (ASX:DXS) Sets APAC Appeal Hearings, Is The Stock Still Cheap?
Dexus (ASX:DXS) shares are in focus after the company outlined the next steps in the APAC legal matter, with the Court setting October hearing dates and multiple appeals and cross appeals now formally scheduled.
See our latest analysis for DEXUS.
Against this backdrop, DEXUS shares have shown a 2.4% 1 day share price return and a 1.9% 30 day share price return. However, the share price is still down 15.7% year to date and total shareholder return over five years has declined 24.4%. This hints at fading longer term momentum despite recent interest around the APAC legal proceedings.
If this legal update has you thinking about where else capital might work harder, it could be a good moment to widen your search and check out the 4 top founder-led companies
After the recent legal update and short term bounce in DEXUS, the share price still sits well below its year to date level, and longer term returns have fallen. Does that skew the balance of risk and potential reward toward buyers, or does it argue for caution at this price?
Most Popular Narrative: 20.1% Undervalued
At a last close of A$5.87, the most followed narrative on Dexus points to a fair value of A$7.35, suggesting a sizeable gap between price and modelled worth.
Portfolio repositioning and targeted capital recycling into high-growth sectors and precincts
especially premium-grade office assets in core CBDs and modern industrial facilities
are expected to drive higher-margin revenues and resilient earnings, as evidenced by record leasing, rising re-leasing spreads, and positive valuation trends in H2 FY25.
Curious what sits behind that A$7.35 figure for Dexus? The narrative leans heavily on earnings power, rich margins and a future profit multiple that assumes investors pay up for those cash flows.
Result: Fair Value of A$7.35 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks for Dexus, including office exposure that could face weaker tenant demand and a development pipeline in which delays or cost pressures would hurt returns.
Find out about the key risks to this DEXUS narrative.
Next Steps
If the mix of concerns and optimism around Dexus feels finely balanced, this is the moment to check the data yourself and decide where you stand. Start by weighing up the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Dexus?
If Dexus has sharpened your focus on where capital works hardest, now is the time to scan wider and pressure test your next move using focused stock lists.
- Target potential mispricings by checking companies that look attractively priced on quality and value through the 9 high quality undervalued stocks
- Prioritise staying power and capital protection by reviewing stocks with resilient financial profiles using the 9 resilient stocks with low risk scores
- Spot underfollowed opportunities early by searching for quality companies that are not yet widely on the radar with the screener containing 12 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com